Who is sponsoring NCT03363321?

NCT03363321 is sponsored by Pfizer.

What condition does NCT03363321 study?

NCT03363321 studies Hemophilia A or B.

What is the status of NCT03363321?

NCT03363321 is currently COMPLETED.

Last reviewed 2021-07-27 · How we verify

PF-06741086 Long-term Treatment in Severe Hemophilia

NCT03363321 PHASE2 COMPLETED Results posted

This study is designed to evaluate the safety, tolerability and efficacy of long-term treatment with PF-06741086 in subjects with severe hemophilia who participated in the 3-month Phase 1b/2 B7841002 study. Additionally, de novo subjects will be recruited into this study.

Details

Lead sponsor	Pfizer
Phase	PHASE2
Status	COMPLETED
Enrolment	20
Start date	Wed May 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Aug 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Hemophilia A or B

Interventions

PF-06741086

Countries

South Africa, Chile, Poland, Switzerland, Croatia, United States, Brazil